NCT00393718View on ClinicalTrials.gov

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

May 31, 2008

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

0.9 mg/day. Injected s.c. (under the skin) once daily.

DRUG

glibenclamide

1.25-2.5 mg tablet. Given orally once or twice daily.

DRUG

placebo

liraglutide placebo. Injected s.c. (under the skin) once daily.

DRUG

placebo

glibenclamide placebo. Given orally once or twice daily.

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY